Stay updated with breaking news from Regarding Use. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Core 2022 development initiatives:Ongoing operation of Company's OnTarget Phase 3 clinical trial of crofelemer for prophylaxis of cancer therapy-related diarrhea (CTD)Initiation and completion in 2H 2022
Press release content from Accesswire. The AP news staff was not involved in its creation.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Product revenue of $359.6 million in the fourth quarter, representing 102% year-over-year growth Remaining performance obligations of $2.6 billion, representing 99% year-over-year growth 5,944... | March 2, 2022
/PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life...